Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Same Sex Marriage in Massachusetts Employee Benefits and Employment Law Implications

Related Content

Internal Revenue Code Section 162(m): Proposed Regulations

Deadline Approaching for Reporting 2024 ISO Exercises and ESPP Share Transfers

A New Form Section 83(b) Election: IRS Form 15620

Minding the Store: Unanticipated ESG Issues Affecting ERISA Fiduciary Supervision

The U.S. Department Of Labor’s New Definition of Fiduciary Investment Advice Is Finalized (Again)

A Token of Appreciation: Cryptoassets and Employee Incentives — a UK Tax Primer

DOL Issues New Rule Raising Minimum Salary Thresholds for Overtime Exemptions

The Department of Labor Finalizes Changes to the QPAM Exemption – A Favored Management Tool Gets Less User-Friendly

The Legal 500 US 2025 Recognizes 44 Goodwin Practices and 172 Lawyers

Chambers USA 2025 Recognizes a Record Number of Goodwin Practices and Lawyers for Exceptional Client Service

Blueprint Medicines To Be Acquired By Sanofi For $9.5 Billion Including Contingent Value Rights

Vigil Neuroscience To Be Acquired by Sanofi For $470 Million and Contingent Value Rights

Understanding Equity Compensation Practices & Trends for Late Stage Private and Newly Public Companies

Kronos Bio To Be Taken Private by Concentra Biosciences

SpringWorks Therapeutics To Be Acquired By Merck KGaA, Darmstadt, Germany For $3.9 Billion

The Supreme Court’s Decision in Cunningham v. Cornell University: Key Takeaways and Impacts

ERISA & Executive Compensation

Employment